Ultomiris Cleared for IgA Nephropathy, Kidney Benefit Unproven

UltomirisWhat to know

30-second read

For Nephrology

Who

Adults with biopsy-confirmed primary IgA nephropathy at risk of progression, already on maximized RAS blockade (ACE inhibitor or ARB), with or without an SGLT2 inhibitor.

What’s new

Ravulizumab (Ultomiris), the first and only C5 complement inhibitor approved for IgA nephropathy, added on top of standard background therapy by IV infusion.

Evidence

I-CAN trial: UPCR fell 46.6% vs 5.6% on placebo at week 34 (43.4% placebo-adjusted); accelerated on a surrogate, not yet shown to slow kidney-function loss.

Big advantage

Tested as an add-on to optimized background therapy, not a replacement; effect seen by week 10; a different mechanism (C5) than Fabhalta (Factor B) or Filspari (ERA/ARB).

Key consideration

Boxed warning for serious, life-threatening meningococcal infection; vaccination required ≥2 weeks before the first dose under the Ultomiris/Soliris REMS.

Availability

Approved 21 Oct 2026; IV infusion roughly every 8 weeks after loading doses. List price for this indication not yet disclosed; billing likely follows existing J1303.

Practice impactConsider as an add-on, not first-line

A reasonable add-on for patients already optimized on RAS blockade who remain at risk of progression — not evidence to replace foundational therapy, and not yet proof the kidney itself benefits; that confirmatory data arrives around 2028.

Read the full physician analysis

Full analysis · 12 min readAstraZeneca’s FDA approval announcement · I-CAN trial (NCT06291376) · FDA/Drugs@FDA (BLA 761108)

FDA granted accelerated approval on 21 October 2026 to AstraZeneca’s Ultomiris (ravulizumab-cwvz) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) who are at risk of disease progression — the first complement C5 inhibitor cleared for the disease, and the third mechanistically distinct drug to reach approval in IgAN inside three years. The approval rests on a surrogate endpoint, proteinuria reduction, not yet on proof that the drug slows the kidney-function decline that actually defines the disease’s outcome.

A third mechanism enters a crowded field

Three years ago, nephrologists managing IgAN had one evidence-based lever beyond supportive care: maximized renin-angiotensin-system (RAS) blockade, with SGLT2 inhibitors increasingly layered on top. Since then, three drugs with three different mechanisms have reached the U.S. market in quick succession — Tarpeyo (targeted-release budesonide, acting on gut mucosal immunity), Filspari (sparsentan, a dual endothelin/angiotensin-II receptor antagonist) and Fabhalta (iptacopan, blocking complement Factor B in the alternative pathway). Ultomiris is the fourth, and the first to work through the complement system’s terminal C5 step rather than its alternative-pathway entry point — the same target Ultomiris already blocks in paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis and neuromyelitis optica spectrum disorder, each approved on the premise that a single long-acting infusion can keep terminal complement activity suppressed for weeks at a time.

Every patient in the trial behind this approval stayed on stable, maximized background IgAN therapy — RAS blockade, with or without an SGLT2 inhibitor, endothelin-receptor antagonist or mineralocorticoid-receptor antagonist, unchanged for at least three months before enrollment and continued throughout. Ultomiris was tested as an add-on to that foundation, not a replacement for it. That design detail matters for patient selection: the trial says nothing about ravulizumab as monotherapy, or about patients who have not yet been optimized on RAS blockade.

What the week-34 data actually showed

I-CAN (NCT06291376) is a global, randomized, double-blind, placebo-controlled Phase 3 trial that planned to enroll roughly 510 adults with biopsy-confirmed IgAN across 28 countries, split 1:1 between ravulizumab and placebo on top of background therapy. The trial carries two co-primary endpoints on two different clocks: a week-34 analysis of 24-hour urine protein-to-creatinine ratio (UPCR), which is what supports this accelerated approval, and a week-106 analysis of estimated glomerular filtration rate (eGFR), which is the confirmatory endpoint AstraZeneca has not yet reported.

I-CAN's week-34 interim analysis

43.4%placebo-adjusted reduction in 24-hour UPCR at week 34 (95% CI, 33.5–51.8)

46.6% vs 5.6%UPCR change from baseline at week 34, ravulizumab vs placebo

36.7% vs 8.5%UPCR change from baseline at week 10 — the effect was already visible by the early readout

~2028expected timing of the week-106 confirmatory eGFR analysis

From AstraZeneca's 21 October 2026 approval announcement and I-CAN trial reporting. The week-106 eGFR analysis, not yet reported, is what continued approval depends on.

An accelerated approval, and what that means

Proteinuria reduction is a surrogate endpoint FDA has used across all four of IgAN’s recently approved drugs, on the premise that a sufficiently large reduction is reasonably likely to predict a slower loss of kidney function over time. It is a premise, not a proof, and AstraZeneca’s own framing of the approval is explicit that whether ravulizumab actually preserves kidney function has not been shown. The pattern has a track record worth knowing: Tarpeyo and Filspari both launched on proteinuria data and later converted to full approval once their own confirmatory eGFR analyses read out positive — Filspari in September 2024, Tarpeyo in December 2023. Fabhalta followed the same arc, converting to full approval in July 2026 after its APPLAUSE-IgAN trial reported a two-year eGFR slope of −3.10 mL/min/1.73m² per year on iptacopan versus −6.12 on placebo — roughly half the rate of decline. Ultomiris is now where those three drugs started: proteinuria down, kidney-function benefit still an open question due around 2028.

Three mechanisms, now all approved in IgA nephropathy

	Ultomiris (ravulizumab)	Fabhalta (iptacopan)	Filspari (sparsentan)
Mechanism	C5 complement inhibitor (terminal pathway)	Factor B inhibitor (alternative complement pathway)	Dual endothelin-A / angiotensin-II receptor antagonist
Route and dosing	IV infusion, loading doses then roughly every 8 weeks	Oral, 200 mg twice daily	Oral, 400 mg once daily (titrated from 200 mg)
U.S. approval status	Accelerated (proteinuria only), 21 Oct 2026; eGFR data due ~2028	Accelerated Aug 2024 → full approval Jul 2026 (eGFR confirmed)	Accelerated Feb 2023 → full approval Sep 2024 (eGFR confirmed)
Headline efficacy signal	I-CAN: 43.4% placebo-adjusted UPCR reduction at week 34	APPLAUSE-IgAN: eGFR slope −3.10 vs −6.12 mL/min/1.73m²/yr at 2 years	PROTECT: UPCR −45% vs −15% (irbesartan) at week 36; eGFR +3.8 at week 110
Boxed warning	Serious, life-threatening meningococcal infection; REMS	Serious infections from encapsulated bacteria (meningococcal, pneumococcal); REMS	Hepatotoxicity; liver-monitoring REMS (relaxed to quarterly, Aug 2025)

No trial has compared these three drugs head-to-head; prescribe from each drug's current label, not this table. Fabhalta and Filspari figures from their own pivotal trials and FDA approval records.

The meningococcal warning that comes with any C5 inhibitor

Ultomiris carries the same boxed warning across every indication it holds: serious, life-threatening or fatal meningococcal infections, a known class effect of blocking terminal complement. The label requires patients to complete or update meningococcal vaccination against serogroups A, C, W, Y and B at least two weeks before the first infusion, unless the risk of delaying treatment outweighs the infection risk — and vaccinated patients remain at increased risk even after seroconversion, since vaccination does not eliminate the risk complement blockade creates. The drug is available only through the Ultomiris and Soliris REMS, a restricted distribution program already in place for its existing indications. For a nephrology practice that has not prescribed a complement inhibitor before, that means a vaccination and monitoring workflow has to exist before the first infusion is scheduled, not after.

AstraZeneca reports the most common adverse events in I-CAN as upper respiratory tract infection, nasopharyngitis and infusion-related reactions, with overall safety described as consistent with Ultomiris’s established profile. That characterization comes from the company’s own reporting rather than an independently published safety analysis; the full adverse-event tables will be worth checking against the label once it is posted to Drugs@FDA.

Where this sits against foundational therapy

Nothing about this approval changes the first step in managing IgAN: RAS blockade, titrated to the maximum tolerated dose, is still the foundation every one of these newer drugs was tested on top of. SGLT2 inhibitors belong in that foundation too — a prespecified IgAN subgroup of the DAPA-CKD trial (270 patients, 254 biopsy-confirmed, dapagliflozin versus placebo, median 2.1 years follow-up) found the composite of 50% eGFR decline, kidney failure or kidney/cardiovascular death in 4% of the dapagliflozin group versus 15% on placebo (hazard ratio 0.29, 95% CI 0.12–0.73), with an eGFR slope of −3.5 versus −4.7 mL/min/1.73m² per year. That evidence predates all four of the newer IgAN-specific drugs and remains the cheaper, oral, generically available option to optimize before reaching for any of them.

Among the newer drugs, the practical split is route of administration as much as mechanism. Fabhalta, Filspari and Tarpeyo are all oral; Ultomiris is an infusion, which means a specialty-infusion site, nursing time, and a REMS-driven vaccination step before the first dose — a materially different operational commitment than writing a prescription. For a patient already struggling with pill burden or adherence, that cuts against Ultomiris; for a patient where infusion-center follow-up is itself a lever for engagement and monitoring, it can cut the other way. No trial has compared any of these four drugs against another head-to-head, so sequencing and combination decisions are extrapolation, not evidence, for now.

Billing today, uncertain tomorrow

Ultomiris already has a Medicare and commercial billing history: it is reported under HCPCS code J1303 (ravulizumab-cwvz, per 10 mg) for its existing indications, and that same code structure is expected to carry over once payers update coverage policy for the new IgAN diagnosis code — no new or indication-specific J-code has been announced, and none would typically be needed for an existing biologic gaining a new indication. What has not been announced is a list price specific to this indication, or any payer’s coverage determination for IgAN; AstraZeneca’s existing Ultomiris OneSource program, which provides reimbursement navigation and copay support for the drug’s other indications, has not been confirmed to extend automatically to IgAN, though that would be the typical pattern. Buy-and-bill economics for a biologic already stocked for PNH or aHUS should transfer operationally; the open question for a nephrology or infusion-center billing team is prior-authorization criteria specific to the new diagnosis, which payers have not yet published four days after approval.

What changes for nephrologists

• Patient selection. Biopsy-confirmed IgAN, already maximized on RAS blockade (and reasonably on an SGLT2 inhibitor), with proteinuria or eGFR trajectory signaling ongoing risk — not a first-line or monotherapy option.
• A fourth option, not a clearly better one. Ultomiris joins Tarpeyo, Filspari and Fabhalta with no head-to-head data; mechanism, route and each drug's own boxed warning are the practical differentiators until more evidence exists.
• Infusion logistics and REMS vaccination have to be arranged before the first dose — a different operational lift than an oral prescription, and a reason some patients and practices will prefer the oral alternatives already on the market.
• Coverage is unsettled. Expect prior-authorization friction until payers publish IgAN-specific criteria; the existing J1303 code and OneSource support infrastructure should carry over, but neither has been formally confirmed for this indication.
• The headline number is proteinuria, not kidney function. Counsel patients accordingly: this accelerated approval has not yet shown that ravulizumab slows the loss of kidney function, and the drug could still face a label change if the week-106 eGFR analysis misses.

Four mechanisms, three years, one disease

1. Dec 2021

   Tarpeyo accelerated approval

   Targeted-release budesonide becomes the first drug approved for IgAN, on proteinuria.

2. Feb 2023

   Filspari accelerated approval

   Sparsentan, a dual endothelin/angiotensin-II receptor antagonist, approved on PROTECT proteinuria data.

3. Dec 2023

   Tarpeyo converts to full approval

   NefIgArd confirms an eGFR benefit over two years.

4. Sep 2024

   Filspari converts to full approval

   PROTECT's eGFR analysis confirms benefit through week 110.

5. Aug 2024

   Fabhalta accelerated approval

   Iptacopan, a Factor B inhibitor, approved on APPLAUSE-IgAN proteinuria data.

6. Jul 2026

   Fabhalta converts to full approval

   Two-year eGFR slope confirms benefit versus placebo.

7. 21 Oct 2026

   Ultomiris accelerated approval

   The first C5 complement inhibitor approved for IgAN, on I-CAN's week-34 proteinuria data.

8. ~2028

   I-CAN's eGFR analysis due

   Week-106 confirmatory data will decide whether Ultomiris converts to full approval.

Frequently asked questions

What did FDA approve on 21 October 2026?

Accelerated approval for AstraZeneca's Ultomiris (ravulizumab-cwvz), a complement C5 inhibitor, to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of disease progression, added on top of maximized background therapy. It is described as the first and only C5 inhibitor approved for IgAN.

Why is this only an accelerated approval, not a full one?

The approval rests on a surrogate endpoint — a 43.4 percent placebo-adjusted reduction in urine protein-to-creatinine ratio (UPCR) at week 34 of the Phase 3 I-CAN trial — not on proof that the drug slows the loss of kidney function. AstraZeneca has not established that benefit; the confirmatory analysis is built around I-CAN's co-primary eGFR endpoint at week 106, expected around 2028.

How does Ultomiris compare to Fabhalta and Filspari?

All three now carry FDA approval in IgAN but work through different mechanisms: Ultomiris blocks complement C5 (IV infusion roughly every 8 weeks), Fabhalta blocks complement Factor B in the alternative pathway (oral, twice daily), and Filspari blocks endothelin and angiotensin II receptors (oral, once daily). Fabhalta and Filspari have each since converted to full approval on confirmed eGFR benefit; Ultomiris has not yet reached that bar. No trial has compared the three head-to-head.